Kicking Off Women's Health Week, the Breast Cancer Research Foundation Expands Online Resources to Empower Women with Trusted Breast Cancer Information
NEW YORK, May 12, 2025 /PRNewswire/ -- Today, to mark the start of Women's Health Week, the Breast Cancer Research Foundation (BCRF) is proud to announce the launch of its first patient-centered offerings: About Breast Cancer and a comprehensive Breast Cancer Glossary of key terms from A to Z. Designed to better serve patients, caregivers, and anyone interested in understanding their own risk, these new resources provide reliable, accessible information, while highlighting the impact of research.
Built to meet the needs of individuals confronting their risk or navigating a breast cancer diagnosis, About Breast Cancer and the Breast Cancer Glossary serve as a trusted, go-to resource.
'Launching these resources to kick off Women's Health Week has never been more salient,' said BCRF President and CEO Donna McKay. 'Breast cancer is the most common cancer in women and incidence is on the rise, most steeply in women under 40. By offering clear, evidence-based guidance alongside insights from BCRF-funded research, the Foundation is providing critical support at every stage of the cancer journey—from prevention and diagnosis to treatment and survivorship.'
Most people in the U.S. turn to the internet when looking for information about cancer. According to 2018 data from the National Cancer Institute, about 70 percent of adults said they searched for health information online while 41 percent have watched health content on social media. But a review of social content reveals that the posts with misinformation achieve higher engagement levels.[1]
'Women deserve more than hope—they deserve real knowledge and empowerment,' said Dr. Dorraya El-Ashry, chief scientific officer at BCRF. 'BCRF Founder Evelyn H. Lauder deeply believed that knowledge is, in fact, power. With the launch of these new resources, we are delivering on that promise and reinforcing BCRF's commitment to research-backed information.'
In today's crowded online environment, the availability of health information has never been greater—nor has the spread of misinformation. As the largest private funder of breast cancer
research worldwide, BCRF is uniquely positioned to offer information developed and produced by a team of experts.
'We approached the creation of About Breast Cancer and the Breast Cancer Glossary with one goal: to provide clear, trustworthy, and accessible information,' said Elizabeth Sile, director of content at BCRF. 'Whether you're facing your risk, undergoing treatment, or navigating a metastatic breast cancer diagnosis, research-backed resources are so critical—especially when misinformation is so prevalent online.'
Highlights include deep dives on:
With these new resources, BCRF strengthens its role not only as a leader in breast cancer research but also as an essential partner in health, providing credible knowledge and supporting every individual touched by breast cancer or those seeking to understand it.
To explore these resources, visit About Breast Cancer and the Breast Cancer Glossary at bcrf.org.
In honor of this launch, the Foundation will be hosting a free webinar this afternoon, May 12, at 12:30pm ET. Registration will close at 11am ET. Join to hear from experts discuss " Emerging Research on Breast Cancer in Younger Women.'
[1] CA: A Cancer Journal for Clinicians, " Cancer misinformation on social media'
Contact:
Sadia Zapp, [email protected]
Breast Cancer Research Foundation
View original content to download multimedia: https://www.prnewswire.com/news-releases/kicking-off-womens-health-week-the-breast-cancer-research-foundation-expands-online-resources-to-empower-women-with--trusted-breast-cancer-information-302451477.html
SOURCE Breast Cancer Research Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
2024 Cell and Gene Therapy Market Set for Breakthrough Growth, Says BCC Research
"Comprehensive Review Highlights Market Growth, Innovation, and Investment Trends Driving the Future of Cell and Gene Therapy Tools, Biomanufacturing, and Gene Synthesis" BOSTON, June 20, 2025 /PRNewswire/ -- BCC Research announces the release of its "2024 Cell and Gene: Research Review," which forecasts strong and steady growth across several key areas of the cell and gene therapy (CGT) industry. This momentum is fueled by ongoing innovation, growing investments, and rising global demand for cutting-edge therapeutic solutions. Key Highlights: • Cell and Gene Therapy Tools, and Reagents: Global Markets: The market is projected to grow from $10.0 billion in 2024 to $16.7 billion by the end of 2029. Compound Annual Growth Rate (CAGR): 10.8%. • Cell Therapy Biomanufacturing: Global Markets: The market is projected to grow from $9.7 billion in 2024 to $16.7 billion by the end of 2029. CAGR: 11.5%. • Gene Synthesis: Technologies and Global Markets: The market is projected to grow from $2.0 billion in 2023 to $4.1 billion by the end of 2028. CAGR: 15.8%. Research Coverage and Insights:This Research Review provides a clear snapshot of the fast-moving cell and gene therapy (CGT) industry. It looks at how these technologies are being used across the entire development pipeline from early research to clinical use and large-scale manufacturing, while also examining the key trends, opportunities, and challenges shaping the market. Key insights include:Broad Application Scope: CGT technologies are being applied in preclinical studies, clinical trials, therapeutic production, viral vector development, and personalized medicine. Investment-Driven Growth: A significant rise in funding and investment is accelerating innovation and expanding the CGT pipeline. Innovation at the Core: Breakthroughs in gene editing, cell modification, and biomanufacturing are pushing the boundaries of what is possible in modern medicine. Cost Challenges: Despite strong momentum, the high cost of therapy development continues to be a limiting factor for broader market adoption. Research Summary:The 2024 Cell and Gene: Research Review exemplifies the type of quantitative market data, analysis, and guidance that BCC Research has provided since 1971. This research review includes highlights and excerpts from the following reports published by BCC Research in 2024: • BIO208C Cell and Gene Therapy Tools, and Reagents: Global Markets. • BIO211B Cell Therapy Biomanufacturing: Global Markets. • BIO251A Gene Synthesis: Technologies and Global Markets. • BIO258A Global Automated and Closed Cell Therapy Market. • BIO225B Global Market for Cell and Gene Therapy. • BIO256A Global Live Cell Imaging Market. • BIO257A Global Single-cell Technologies Market. After accessing this Research Review and benefiting from its insight, we encourage you to explore the full portfolio of market research reports for a deeper understanding of each topic. BCC Research remains your trusted partner in market intelligence, and we are committed to supporting your future insights and decisions. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. For further information on any of the reports or to make a purchase, contact us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301For media inquiries, email press@ or visit our media page for access to our market research data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business Wire
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX ® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation, and a final decision on the application is expected in the coming months. 'Neuroendocrine tumors are difficult to treat given their indolent nature and lack of robust responses to traditional oncology agents. This often results in people living with this type of cancer for long periods of time and running out of effective options, underscoring the critical need for new treatments following disease progression,' said Amy Peterson, M.D., Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer. 'The CHMP's recommendation is a pivotal milestone for our partner Ipsen as they work to bring CABOMETYX to patients in Europe, and we look forward to hearing the European Commission's decision in the coming months.' The CHMP recommendation is based on results from the phase 3 CABINET pivotal trial, which is evaluating CABOMETYX compared with placebo in two cohorts of patients with previously treated NET: advanced pNET and advanced epNET. CABINET was the basis for the U.S. Food and Drug Administration (FDA) approval of CABOMETYX in March 2025 for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. Final progression-free survival (PFS) results were presented at the 2024 European Society for Medical Oncology Congress and published in The New England Journal of Medicine. About CABINET (Alliance A021602) CABINET (Randomized, Double-Blinded, Phase III Study of CAB ozantinib versus Placebo I n Patients with Advanced NE uroendocrine T umors After Progression on Prior Therapy) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and is being led and conducted by the NCI-funded Alliance for Clinical Trials in Oncology with participation from the NCI-funded National Clinical Trials Network, as part of Exelixis' collaboration through a Cooperative Research and Development Agreement with the NCI's Cancer Therapy Evaluation Program. CABINET is a multicenter, randomized, double-blinded, placebo-controlled phase 3 pivotal trial that enrolled a total of 298 patients in two separate cohorts (pNET and epNET) in the U.S. at the time of the final analysis. Patients were randomized 2:1 to cabozantinib (60 mg) or placebo; each cohort was randomized separately and had its own statistical analysis plan. The trial was stopped early after an interim analysis showed superior efficacy associated with cabozantinib as compared to placebo in each of the two cohorts. Patients with epNET had primary tumors arising in the gastrointestinal (GI) tract, lung, unknown primary sites and other organs. Patients must have had measurable disease per RECIST 1.1 criteria and must have experienced disease progression or intolerance after at least one U.S. FDA-approved line of prior systemic therapy other than somatostatin analogs. The primary endpoint in each cohort was PFS per RECIST 1.1 by blinded independent central review. Secondary endpoints included overall survival, objective response rate and safety. More information about this trial is available at About NET NET are cancers that begin in the specialized cells of the body's neuroendocrine system. 1 These cells have traits of both hormone-producing endocrine cells and nerve cells. 1 It is estimated that 161,000 to 192,000 people in the U.S. are living with unresectable, locally advanced or metastatic NET. 2 The number of people diagnosed with NET has been increasing in recent decades. 3 Functional NET release peptide hormones that can cause debilitating symptoms, like diarrhea, hypertension and flushing, while symptoms of non-functional NET are related primarily to tumor growth. 4,5,6,7,8 Most NET take years to develop and grow slowly, but eventually all patients with advanced or metastatic NET will develop refractory and progressing disease. 9,10 NET can start in the pancreas (pNET), where they tend to be more aggressive, with a five-year survival rate of only 23% for advanced disease. 1,11 NET can also develop in any part of the body, but most commonly start in the GI tract or in the lungs, where they have historically been referred to as carcinoid tumors and are more recently called epNET. 1 The five-year survival rates for advanced GI and lung NET tumors are 68% and 55%, respectively. 12,13 For advanced NET patients, treatment options include somatostatin analogs, chemotherapy, molecular targeted therapy and peptide-receptor radionuclide therapy. 14 About CABOMETYX ® (cabozantinib) In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and in combination with nivolumab as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET; and adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated epNET. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation. Thrombotic Events: CABOMETYX can cause arterial or venous thromboembolic event. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events. Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis. Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose. Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE. Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity. Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity. Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome. Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose. Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS. Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment. Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4). Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity. Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose. ADVERSE REACTIONS The most common (≥20%) adverse reactions are: CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation. CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. DRUG INTERACTIONS Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice. Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John's wort. USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose. Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment. Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established. Please see accompanying full Prescribing Information You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of CABOMETYX for patients with previously treated advanced neuroendocrine tumors; the regulatory review process in the EU, including the expected timing for a final decision from the EC; Exelixis' or its partner Ipsen's ability or plans to support these new indications for patients in Europe; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: complexities and the unpredictability of the regulatory review and approval processes in the EU and elsewhere, including the risk that the EC may not approve CABOMETYX for the treatment of adult patients with unresectable or metastatic, well-differentiated epNET and pNET who have progressed following at least one prior systemic therapy other than a somatostatin analogue in a timely fashion, if at all; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib; Exelixis' dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications and their adherence to their obligations under relevant collaboration agreements; Exelixis' ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting Exelixis and its partners to obtain regulatory approval for cabozantinib in new indications; and other factors detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.
Yahoo
2 days ago
- Yahoo
Japan's Top Eczema App, Atopiyo, Launches in the US: Pioneering Digital Eczema Care
11-time award winner, university-backed, delivers what 31M patients need most — visual tracking, peer support, AI analysis CHIBA, Japan, June 19, 2025 /PRNewswire/ -- Living with eczema isn't just a physical challenge—it affects mental health, confidence, and daily life. That's why ATOPIYO, Japan's leading eczema app, is launching in the U.S., where 31 million people are affected. With a growing community of over 29,000 users, ATOPIYO empowers individuals with eczema to track their symptoms, document treatment progress, and connect with others—all through a simple and intuitive visual platform. A New Way to Manage Eczema During the hot summer months, monitoring eczema symptoms becomes especially important. ATOPIYO makes this easier by allowing users to photograph their skin, meals, and medications—helping them visualize their treatment journey and share it with others over time. "This is the best eczema management app I've used so far. I hope you continue improving it! Being able to compare my symptoms with others who share the same condition—it's groundbreaking."— Google Play reviewer (JP) 3 Key Features: Visual Tracking – Snap photos to easily record and organize symptoms, diet, and medication. Peer Support – Share experiences and connect with others facing similar struggles. Anonymous & Free – Secure platform with no cost barriers to care. "Posting anonymously helps me find others with similar symptoms and treatments—it's incredibly helpful. Just seeing someone say 'I get it' when I'm feeling down from the itching or appearance is a relief. I feel less alone and more motivated to get better. Recording and sharing gives me a surprising sense of positivity. I also hope these posts contribute to new treatment development." — App Store reviewer (JP) Smartphone-Powered AI Analysis On May 20, 2025, research published in the prestigious medical journal Allergy highlighted AI technology co-developed by Keio University, Kyoto Prefectural University of Medicine, Teikyo University, and ATOPIYO, which evaluates eczema severity from smartphone photos. This breakthrough technology could be integrated into future app versions, enabling medical-grade assessments at home. Keio University: About ATOPIYO ATOPIYO was developed by Ryotaro Ako, who suffered from severe eczema as a child. Inspired by his experience and supported by his wife, a licensed pharmacist. Since its launch in Japan, ATOPIYO has grown to over 29,000 users and accumulated more than 66,000 user-submitted images. It has received 11 national awards, including the Minister of Health, Labour and Welfare Award, and is currently collaborating with 7 national and university hospitals to support eczema-related research and innovation. "Eczema doesn't stop—not even during sleep—and its visibility can take a serious toll on mental health. ATOPIYO was created to help people manage their symptoms, share experiences, and support each other on the path to recovery."— Ryotaro Ako, Founder of ATOPIYO App Information App Name: Visual Eczema Care App - ATOPIYOPrice: Free (Anonymous use)Category & Age Rating: Google Play – Medical / 12+, App Store – Medical / 17+AppStore: GooglePlay: Contact InformationCompany: Atopiyo LLCLocation: Chiba, JapanEmail: View original content to download multimedia: SOURCE Atopiyo LLC Sign in to access your portfolio
